FDA’s new Rare Disease Framework emphasizes fit-for-purpose drug development and earlier patient input. Explore what it could mean for rare disease sponsors....
In policy meetings and committee rooms across the country, newborn screening conditions are regularly scored, debated, and weighed. Leaders evaluate analytical validity, treatment efficacy, and system capacity. But every so...
Learn how sponsors can identify clinical trial recruitment problems early, address enrollment risks proactively, and protect study timelines before delays occur....
Learn why newborn screening is one of the most important public health tools for rare disease diagnosis, early intervention, health equity, and improved patient outcomes....
Learn how sponsors can build trust with patient communities before recruitment begins and why early engagement strengthens long-term recruitment success....
Patients are often willing to participate in clinical trials but face barriers related to access, travel, costs, and eligibility. Learn how sponsors can improve clinical trial enrollment by addressing participation...
Learn how patient storytelling can improve clinical development by revealing patient priorities, reducing trial barriers, strengthening advocacy engagement, and supporting more patient-centered study design....
Learn how underperforming study sites increase operational costs through recruitment delays, retention challenges, data quality issues, and inefficient study execution....
Learn how early patient input can help sponsors avoid costly protocol amendments, reduce trial burden, improve recruitment readiness, and strengthen participant engagement....
